Building Life

Founded in 2013, Arcturus is a leader in RNA medicines.

Placeholder

Arcturus Therapeutics

  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE
  • Janssen Pharmaceuticals, Inc entered into a research collaboration and worldwide license agreement with Arcturus to develop and commercialize RNA-based drug products.Janssen Pharmaceuticals, Inc entered into a research collaboration and worldwide license agreement with Arcturus to develop and commercialize RNA-based drug products.READ MORE
  • Arbutus obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleomonomer Agent (UNA) from Arcturus.Arbutus obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleomonomer Agent (UNA) from Arcturus.

Proprietary Technologies

UNA and LUNAR™ Will Revolutionize RNA Medicines

TRANSPORTERS RECEPTORS ANTIBODIES ENZYMES TALEN GPCR’S HORMONES CHAPERONES CAR-T CRISPR
Trans-membrane Proteins Secreted Proteins Intracellular Proteins Engineered Antigens Engineered Nucleases
READ MORE

RNA Medicines

  • Antisense RNA
    Antisense RNA works by binding to messenger RNA (mRNA) and physically preventing the cell from translating the mRNA into protein. READ MORE
  • Gene Editing
    Human DNA has roughly 20 000 genes. Each gene contains the code needed to make one or more proteins. READ MORE
  • MicroRNA
    MicroRNA medicines can be used to treat complex diseases like cancer that are caused by many different malfunctioning proteins. READ MORE
  • mRNA
    Messenger RNA (mRNA) therapeutics can treat diseases caused by a lack of protein, or by defective proteins, such as Duchenne muscular dystrophy and cystic fibrosis. READ MORE
  • RNA
    RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics. READ MORE
  • RNAi
    RNA interference (RNAi) is a natural mechanism used by the body to turn genes off without permanently changing DNA. READ MORE
  • siRNA
    Small interfering RNA (siRNA) medicines can treat viral infections like hepatitis B and diseases like Huntington’s disease that are caused by malfunctioning proteins. READ MORE

Pipeline

name

LUNAR-OTC

indication
OTC Deficiency
api
mUNA

INTERNAL mUNA PROGRAMS

PRECLINICAL

name

LUNAR-HBV

indication
Hepatitis B
api
siUNA

PARTNERED PROGRAMS

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
siUNA

LICENSED PROGRAMS

CLINICAL

News & Events

  • April 11, 2017

    Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego

    • April 11 2017
    • 0
    read more
  • April 10, 2017

    Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego

    • April 10 2017
    • 0
    read more
  • April 6, 2017

    Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery

    • April 6 2017
    • 0
    read more
  • April 3, 2017

    Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression

    • March 31 2017
    • 0
    read more
  • March 30, 2017

    Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory

    • March 29 2017
    • 0
    read more
  • March 10, 2017

    Arcturus Therapeutics featured by SCRIP Intelligence publication

    • March 10 2017
    • 0
    read more
  • March 9, 2017

    Arcturus To Present at BD Boston Conference

    • March 8 2017
    • 0
    read more
  • March 7, 2017

    BioCentury featuring Arcturus Therapeutics in an article called Getting the Message

    • March 7 2017
    • 0
    read more
  • March 3, 2017

    Arcturus To present at UCSF Rare Disease Symposium: “A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases”.

    • March 3 2017
    • 0
    read more